Table 2 Efficacy end-points (%) at 30-day follow-up
From: Systematic adjudication of myocardial infarction end-points in an international clinical trial
| Â | Eptifibatide* | Placebo | Absolute | Relative | Â | Number needed |
|---|---|---|---|---|---|---|
End-point | (n = 4722) | (n = 4739) | reduction | reduction | P | to treat |
Death or infarction | Â | Â | Â | Â | Â | Â |
   Clinical events committee | 14.2 | 15.7 | 1.5 | 9.6 | 0.042 | 10.4 |
   Site investigator | 8.1 | 10.0 | 1.9 | 19.0 | 0.0007 | 5.3 |
Myocardial infarction | Â | Â | Â | Â | Â | Â |
   Clinical events committee | 12.6 | 13.6 | 1.0 | 7.4 | 0.137 | 13.5 |
   Site investigator | 6.2 | 7.8 | 1.6 | 20.5 | 0.002 | 4.9 |